Precipio (NASDAQ:PRPO) Issues Quarterly Earnings Results

Precipio (NASDAQ:PRPO) issued its earnings results on Friday. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($2.00) by $1.88, Zacks reports. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The business had revenue of $7.02 million during the quarter, compared to the consensus estimate of $1.68 million.

Precipio Price Performance

Shares of NASDAQ:PRPO traded up $0.29 on Friday, hitting $23.50. The company’s stock had a trading volume of 75,806 shares, compared to its average volume of 115,687. The company has a 50-day simple moving average of $23.42 and a 200 day simple moving average of $25.02. Precipio has a 1 year low of $13.80 and a 1 year high of $33.63. The company has a market capitalization of $42.06 million, a PE ratio of -50.00 and a beta of 1.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.33.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Friday, July 17th. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Precipio currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 789 shares in the last quarter. Renaissance Technologies LLC grew its stake in Precipio by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after buying an additional 1,400 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of Precipio in the 3rd quarter worth $194,000. 10.45% of the stock is currently owned by institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.